PL BioScience Launches World's Only Patented Gamma-irradiated Human Platelet Lysate
AACHEN, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced the launch of ELAREM™ Ultimate-FD PLUS, the only gamma-irradiated, GMP-grade Human Platelet Lysate produced in Germany using a globally patented process. With the increasing demand for safe, xeno-free, ethically sourced cell culture supplements in cell therapy, regenerative medicine, and biopharmaceutical manufacturing, ELAREM™ Ultimate-FD PLUS answers a critical industry need: a virus-inactivated, animal-free, and EU-manufactured alternative that meets the highest quality standards.
'We are thrilled to bring the only gamma-irradiated Human Platelet Lysate produced in Europe to the dynamic field of cell and gene therapy,' said Dr. Hatim Hemeda, Chief Executive Officer of PL BioScience. 'This product isn't just a milestone for Europe – it's a globally unique offering. With comprehensive patent protection and fully EU-based production, ELAREM™ Ultimate-FD PLUS ensures a stable supply chain and offers global manufacturers a high-quality, regulatory-ready solution that meets the highest international standards.'
Cell culture supplements are essential for growing cells in the laboratory. They play a critical role in the development and manufacturing of advanced therapies like cell and gene therapies. Traditionally, these supplements often contain components derived from other species, such as fetal bovine serum (FBS). These animal-derived products carry potential safety risks, for example bacterial or viral contamination, and pose ethical concerns. HPL offers a fully human-derived, xeno-free alternative that is safe, consistent, and sustainable.
ELAREM™ Ultimate-FD PLUS takes this one step further. Through a proprietary gamma-irradiation process, the product undergoes viral inactivation to add an extra layer of safety and regulatory assurance. The gamma-irradiated, xeno-free, fibrinogen-depleted, and anticoagulant-free product complies with the relevant GMP (Good Manufacturing Practice) guidelines. This makes it especially suitable for cell manufacturing applications where viral reduction is critical, such as potential use in clinical trials.
About Human Platelet Lysate:
Human Platelet Lysate (HPL) is an innovative, human-derived cell culture supplement used to support the growth and expansion of cells in research and clinical development, particularly in cell therapy, stem cell, and regenerative medicine applications. It is produced from donated human blood platelets that are no longer suitable for transfusion and would otherwise be discarded – making it a sustainable and resource-efficient alternative to traditional cell culture supplements.
In cell culture, HPL provides essential growth factors and nutrients that promote healthy, robust cell proliferation. Compared to conventional products such as Fetal Bovine Serum (FBS), which is harvested from unborn calves, HPL delivers more consistent results in cell growth, is free from animal-derived pathogens, and aligns with the increasing demand for animal-free and ethically responsible laboratory practices.
ELAREM™, PL BioScience's line of xeno-free HPL products, can be used from early-stage research to the production of cell-based therapies under Good Manufacturing Practice (GMP) conditions for the treatment of patients.
About PL BioScience:
Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HPL), offering a complete portfolio of HPL products tailored for various use cases. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translations of regenerative medicine breakthroughs – from the lab to patients in need. With ELAREM™ Ultimate-FD PLUS, PL BioScience produces the only globally patented gamma-irradiated HPL product. For more information on PL BioScience and the ELAREM™ product offerings, visit: https://www.pl-bioscience.com/
Contact:
Dr. Hatim Hemeda, CEO
PL BioScience GmbH
+49(0)24195719-100
[email protected]
Media contact:
MC Services AG
Raimund Gabriel, Dr. Regina Lutz
+49 (0)89 210 228 0
US: Catherine Featherston
+1-203-444-4393
E-Mail: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Dozing Breaks Ground on North America's Largest Low-Carbon Cement Mill
CHICAGO, June 10, 2025 /PRNewswire/ -- Ozinga has officially broken ground on a cutting-edge low-carbon cement manufacturing facility in East Chicago, Indiana. Equipped with one of North America's largest vertical roller mills, the new plant will produce one million tons of low-carbon cementitious materials annually. Strategically located with direct access to rail, truck, and water (via the Great Lakes and the inland waterways of the U.S.), the facility will serve customers across the United States and Canada, reinforcing Ozinga's commitment to sustainable infrastructure, supply chain resilience, and American manufacturing. "Ozinga has always believed that true innovation isn't just about progress, it's about purpose," said Marty Ozinga, CEO of Ozinga. "This facility is more than a plant. It's a commitment to the future of American manufacturing, to sustainable building, and to strengthening American communities for generations to come." Investing in Communities and American Manufacturing The East Chicago facility and its related operations are projected to create approximately 150 construction and long-term full-time jobs, fueling regional economic growth. Operations are expected to begin in 2026. "This is the kind of investment that strengthens communities and provides real opportunity for local families," said Anthony Copeland, Mayor of East Chicago. With over 2,500 employees nationwide, Ozinga continues to prioritize sustainability, community development, and innovation. The East Chicago facility marks a major milestone in the company's mission to deliver net zero concrete by 2030. Reducing Emissions, Strengthening Supply Chains Concrete is the backbone of modern infrastructure essential to homes, schools, hospitals, roads, and bridges. Yet traditional Portland cement, its core ingredient, accounts for nearly 7% of global CO₂ emissions. In 2024, the United States imported nearly 30 million tons of cement, leaving infrastructure projects vulnerable to supply chain instability and trade volatility. Ozinga's East Chicago facility directly addresses this challenge. By producing domestic low-carbon cements, it will reduce dependence on imports and dramatically lower embodied carbon in construction materials, supporting both environmental goals and economic resilience. Powered by North America's Largest Low-Carbon Vertical Roller Mill At the heart of the facility is the MVR5300-C6 vertical roller mill from Gebr. Pfeiffer, the largest of its kind in North America. With six independent rollers and unmatched throughput capacity, the mill maximizes energy efficiency while minimizing carbon emissions. "This isn't just a plant—it's a technological milestone," said Timothy Burden, President of Gebr. Pfeiffer Americas. "The MVR5300-C6 sets a new benchmark for sustainable cement production." The facility will produce ASTM C989-compliant low-carbon slag cement, as well as proprietary blends under Ozinga's CarbonSense™ brand, meeting ASTM C1157 performance standards and delivering up to 80% reductions in embodied carbon. Once fully operational, the plant is projected to offset more than 700,000 metric tons of CO₂ emissions annually, a significant reduction in the carbon footprint of U.S. construction. Driving Innovation Through Collaboration Ozinga's leadership in sustainable building materials has been strengthened by partnerships with Meta, the University of Illinois Urbana-Champaign, and other industry leaders. These collaborations have yielded AI-optimized low-carbon concrete, used in Meta's DeKalb, IL data center, and enabled a 64% reduction in embodied carbon at the award-winning Amazon Web Services New Carlisle, IN data center, setting a new industry benchmark. The new East Chicago facility is a timely response to the growing demand for low-carbon concrete in data center construction and other mission-critical infrastructure projects across North America. About OzingaOzinga is a fifth-generation, family-owned American company providing concrete, bulk materials, and construction solutions for commercial, industrial, and residential projects. Committed to service, learning, and entrepreneurship, Ozinga continues to develop environmentally responsible products and practices that make a positive impact and shape the future of the built environment. Contact: Joe BrettellProsody Consulting(571) 230-3411jbrettell@ View original content to download multimedia: SOURCE Ozinga
Yahoo
41 minutes ago
- Yahoo
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 18, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests. Webcast Information: Date: Wednesday, June 18, 2025 Time: 9:30 a.m. ET A live webcast and replay will be accessible from the Company's website at and at About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK's proprietary platform is designed to restore immune balance and drive cytotoxic immune responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK's lead asset, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy currently in clinical development for the treatment of graft-versus-host disease (GvHD), solid tumors, and critical pulmonary immune collapse. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable tumor- and tissue-specific immune activation with broad potential application. With a scalable, cryopreserved manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies that are accessible, durable, and applicable across a wide range of indications. For more information, visit or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Investor Contact917-362-1370 investor@ Media Contact781-674-4428communications@ in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
Syntiant to Demonstrate Ultra-Low-Power Automotive AI Innovations at AutoSens and InCabin 2025
Multi-Modal, Always-On Security Solutions Bring EV-Level Intelligence to Internal Combustion-Engine Vehicles IRVINE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Syntiant Corp., the recognized leader in low-power edge AI deployment, today announced it will showcase two of its vehicle sensing technologies at AutoSens and InCabin 2025, June 10-12 at Huntington Place in Detroit (Booth #210). Syntiant's multimodal automotive solutions are designed to enhance vehicle safety and user experiences by enabling always-on audio and vision intelligence at the edge, without draining the battery or relying on cloud connectivity. Live demonstrations will include: Low-power camera security system. Ideal for applications such as parked vehicle monitoring and fleet management, this AI perimeter security solution keeps dash or external cameras in an ultra-low-power standby mode while continuously monitoring for specific audio or visual cues, such as footsteps, voices or motion near the vehicle. Upon detection, the system instantly activates high-resolution cameras to begin recording at under 200 mW, preserving energy while improving real-time incident capture. In contrast, traditional always-on security systems can draw over 100 watts, limiting them to electric vehicles with large batteries. Syntiant's solution delivers comparable performance at a fraction of the power, enabling always-on security for virtually any vehicle. External sound detection using vibration sensors. Traditional microphones placed outside of a vehicle are prone to failure in harsh environments. Rain, dust, snow and even car washes might permanently damage the device. Syntiant's V2S vibration sensors mounted on a vehicle's door, windshield or trunk, detect motions caused by external sounds, enabling features like emergency vehicle detection and hands-free voice commands (e.g., 'open trunk'), without the exposure-related limitations of conventional microphones. By effectively turning the vehicle's surface into the microphone, the Syntiant V2S provides a durable and reliable alternative for external sound detection. 'Enhanced sensing capabilities are essential to meet the demands of smarter vehicles, especially when driving conditions are less than ideal,' said Greg Doll, SVP and GM of Syntiant's sensors business unit. 'By integrating sensors, AI hardware and software, we have developed low-power automotive intelligence that can enable vehicles to be more responsive to their surroundings, and ultimately more useful to drivers and passengers.' Syntiant's complete automotive solutions are powered by a combination of its Neural Decision Processors, ML models, sensors and microphones. These technologies power a broad range of intelligent automotive features, including voice and siren detection, blind spot alerts, facial recognition, battery management, in-cabin monitoring and other Advanced Driver Assistance Systems (ADAS). More information about Syntiant's automotive solutions can be found at AutoSens and InCabin 2025 OEMs and Tier 1 suppliers can register at no cost by visiting Partners, including distributors, representatives and design partners, are eligible for a 30% discount, available upon request by emailing info@ To schedule a private demo or meeting with Syntiant (Booth #210), please contact info@ About Syntiant Founded in 2017 and headquartered in Irvine, Calif., Syntiant® is Making Edge AI a Reality™ by delivering highly efficient processor, sensor and software solutions. With more than 100 million purpose-built silicon and ML models deployed, along with billions of MEMS microphones and sensors, Syntiant's technology is powering edge AI applications for speech, audio, sensor and vision processing worldwide. From earbuds to automobiles, the company's turnkey solutions enable advanced edge AI capabilities across diverse consumer and industrial use cases. More information on the company can be found by visiting or by following Syntiant on X @Syntiantcorp or LinkedIn. Media Contact: George Medici/Natalie MuPondelWilkinson or nmu@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
